Evidence map›Paper›PMID 37583314›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.

Kimberly Snow Caroti, Alok A Khorana, Cecilia Becattini, Agnes Y Y Lee, Anders Ekbom, Marc Carrier, Alexander T Cohen, Christopher Brescia, Khaled Abdelgawwad, George Psaroudakis and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 6 countries.

Kimberly Snow CarotiSchool of Pharmacy, University of Connecticut, West Suffield, Connecticut, USA.
Alok A KhoranaCleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio, USA.
Cecilia BecattiniDepartment of Internal and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
Agnes Y Y LeeDivision of Hematology-Department of Medicine, University of British Columbia and BC Cancer, Vancouver, Canada.
Anders EkbomUnit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Marc CarrierDepartment of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Canada.
Alexander T CohenDepartment of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK.
Christopher BresciaFreshtech IT, LLC, East Hartford, Connecticut, USA.
Khaled AbdelgawwadBayer AG, Berlin, Germany.
George PsaroudakisBayer AG, Berlin, Germany.
Marcela RiveraBayer AG, Berlin, Germany.
Bernhard SchaeferBayer AG, Berlin, Germany.
Gunnar BrobertBayer AG, Berlin, Germany.
Craig I ColemanSchool of Pharmacy, University of Connecticut, West Suffield, Connecticut, USA.ORCID 0000-0003-4868-7158
Bayer (Germany) · DEHartford Hospital · USAlltech (United States) · USCleveland Clinic · USKarolinska Institutet · SEKing's College London · GBUniversity of British Columbia · CAUniversity of Ottawa · CAUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated venous thromboembolism (CAT) guidelines recommend direct oral anticoagulants as alternatives to low-molecular-weight heparin (LMWH) in most patients. This study compared the effectiveness and safety of rivaroxaban versus LMWH for a broad CAT cohort. The cohort study used electronic health data from January 2012 to December 2020 to evaluate patients with active cancer experiencing acute venous thromboembolism (VTE) and treated with rivaroxaban or LMWH. Propensity score-overlap weighted hazard ratios (HRs) and 95% confidence intervals (CIs) for VTE, bleeding-related hospitalization, and all-cause mortality were calculated. In total, 4935 patients were identified (27.9% on rivaroxaban and 72.1% on LMWH). The cancer types included gastrointestinal (29.4%), genitourinary (26.2%), lung (24.0%), breast (19.7%), and hematologic (14.4%). Rivaroxaban was associated with a reduction in recurrent VTE versus LMWH among all patients with cancer (HR = 0.78; 95%CI = 0.61-0.99) at 3 months. No differences in bleeding-related hospitalization or all-cause mortality were observed. Directionally similar results to those at 3 months were observed at 6 months for all outcomes. In conclusion, we observed fewer recurrent VTE cases and no increase in bleeding-related hospitalizations with rivaroxaban versus LMWH at 3 months in this patient cohort with various cancer types.

Indexed as

NeoplasmsVenous ThromboembolismAnticoagulantsCohort StudiesHemorrhageHeparin, Low-Molecular-WeightHumansRivaroxabanAnticoagulantsHeparin, Low-Molecular-WeightRivaroxabananticoagulantsheparinlow-Molecular-Weightneoplasmsrivaroxabanvenous thromboembolism

Identifiers

PMID37583314
PMCPMC10467381
OpenAlexW4385850365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.